Key Findings
Cellectis’ CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). This is a landmark achievement, as it is the first allogeneic CAR T-cell therapy to receive RMAT designation while in a pivotal trial for R/R B-ALL. Further underscoring its potential, final Phase 1 data from the BALLI-01 clinical trial for lasme-cel were presented at the European Hematology Association (EHA) 2026 annual meeting, demonstrating a remarkable 100% overall response rate (ORR) in the target Phase 2 patient population with a manageable safety profile.
Technical and Clinical Details
The clinical data for lasme-cel highlights its potent anti-leukemic activity and favorable safety profile. The BALLI-01 study, conducted in adult patients with R/R B-ALL, aimed to evaluate the potential of this off-the-shelf CD22-targeting allogeneic CAR T-cell therapy. Researchers reported rapid and durable responses, with a significant proportion of patients achieving complete remission. In terms of safety, adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were generally manageable. This suggests that the inherent alloimmune reactions associated with allogeneic therapies are sufficiently controlled in the context of lasme-cel, potentially offering an improved safety margin compared to some autologous CAR T therapies. Additionally, Cellectis presented preliminary Phase 1 data for eti-cel (UCART20x22), a dual CD20/CD22-targeting allogeneic CAR T-cell therapy, from the NATHALI-01 study in R/R B-cell non-Hodgkin lymphoma patients. This dual-targeting approach aims to mitigate antigen escape and enhance therapeutic efficacy across diverse B-cell malignancies.
Background and Industry Context
R/R B-ALL remains a challenging malignancy with limited treatment options and poor prognosis, particularly in adult patients. While existing treatments, including chemotherapy, hematopoietic stem cell transplantation, and certain autologous CAR T-cell therapies, have shown efficacy, they are often associated with manufacturing delays and dependency on the patient’s physiological fitness. Allogeneic CAR T-cell therapies like lasme-cel offer a significant advantage by being ‘off-the-shelf,’ enabling rapid accessibility and timely treatment for a broader patient population. The RMAT designation, granted by the FDA for regenerative medicine products addressing serious conditions with unmet medical needs and preliminary clinical evidence of benefit, underscores the high regard the FDA holds for lasme-cel’s potential clinical impact. This designation facilitates expedited development and review processes.
Strategic Significance and Outlook
The RMAT designation for lasme-cel and the compelling Phase 1 data presented at EHA represent critical milestones towards the commercialization of allogeneic CAR T-cell therapies. Cellectis is now poised to accelerate its pivotal trials for lasme-cel, moving closer to regulatory approval. The success of allogeneic CAR T therapies would mark a substantial advancement over traditional autologous approaches in terms of manufacturing scalability, cost-effectiveness, and patient access, potentially benefiting a larger population of hematologic cancer patients. Furthermore, the development of dual-targeting strategies like eti-cel signifies an ongoing evolution in CAR T-cell therapy design, aimed at overcoming tumor heterogeneity and antigen escape, thereby broadening the potential applications across various cancer types.
Comments